Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health,
Industry
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Policies or Program
|
Health,
Industry
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
Health,
Industry
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
Environment,
Industry
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Health,
Industry
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
Health,
Industry
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
Health,
Industry
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
Health,
Industry
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
Health,
Industry
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Foreign Affairs,
Health,
Industry
|
Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Policies or Program
|
Health,
Industry
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
Health,
Industry
|
Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Health,
Industry
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry,
Intellectual Property
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
Health,
Industry,
Intellectual Property
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
Health,
Industry,
Intellectual Property
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
Health,
Industry
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Health,
Industry
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
Health,
Industry,
Research and Development,
Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
Health,
Industry
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Health,
Industry,
Research and Development
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
Health,
Industry
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Policies or Program
|
Health,
Industry
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Policies or Program
|
Health,
Industry
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Free trade treaty agreement as they relate to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: